Development

ISAR Bioscience develops new therapies based on ist research projects. Our focus is on several preclinical development projects.

Development

ISAR Bioscience develops new therapies based on ist research projects. Our focus is on three preclinical development projects.

development projects

Antibodies against Alzheimer’s dementia

ISAR Bioscience develops novel antibodies directed against a protein relevant for Alzheimer’s disease. First results are encouraging.

New immunotherapies from induced stem cells

ISAR Bioscience aims to teach iPS cells how to fight autoimmune diseases in an effective and sustained manner.

Lipid nanoparticles (LNPs) for RNA medicine and Tolero-LNPs

Lipid nanoparticles protect novel RNA-based drugs and deliver them to their sites of action in the body. ISAR Bioscience aims to reduce side effects and to make them more powerful.

Therapy of lung diseases

Together with partners in Munich and around the world, ISAR Bioscience is developing novel therapies for the treatment of acute and chronic lung diseases.

Devel­op­ment

Devel­op­ment

devel­op­ment projects

Anti­bod­ies against Alzheimer’s dementia

New immun­o­ther­apies from induced stem cells

Lipid nan­o­particles (LNPs) for RNA medi­cine and Tolero-LNPs

Ther­apy of lung diseases

Development

Development

development projects

Antibodies against Alzheimer’s dementia

New immunotherapies from induced stem cells

Lipid nanoparticles (LNPs) for RNA medicine and Tolero-LNPs

Therapy of lung diseases